Want to see OSTX full AI Analyst Report?
Top Page
OS Therapies Incorporated
(NYSE MKT:OSTX)
Select Model
Select Model
Rating:47Neutral
Price Target:
$1.50
▲(4.17% Upside)
Action:Reiterated
Date:07/07/26
Overall score is weighed down primarily by weak financial performance (pre-revenue, widening losses, and ongoing cash burn) and only modest technical support (trading below key short-term moving averages). Offsetting factors include positive regulatory momentum and financing that may extend runway, but valuation remains difficult to support given negative earnings and no dividend.
Positive Factors
Regulatory Progress
A formal EMA rolling review and regulator alignment on primary endpoints create a clearer pathway to conditional approval and coordinated global filings. This durable regulatory momentum reduces development uncertainty, supports planned Phase 3 timing and helps position OST-HER2 for market access and reimbursement planning.
Negative Factors
Pre-Revenue Status
OS Therapies remains clinical-stage with no commercial revenues; persistent negative gross profit and widening operating losses show the business is not yet self-sustaining. Long-term value depends entirely on successful clinical outcomes and approvals, making execution risk and binary trial results central to future viability.
Read all positive and negative factors
Positive Factors
Negative Factors
Regulatory Progress
A formal EMA rolling review and regulator alignment on primary endpoints create a clearer pathway to conditional approval and coordinated global filings. This durable regulatory momentum reduces development uncertainty, supports planned Phase 3 timing and helps position OST-HER2 for market access and reimbursement planning.
Read all positive factors
OS Therapies Incorporated (OSTX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$76.61M
Dividend YieldN/A
Average Volume (3M)874.96K
Price to Earnings (P/E)―
Beta (1Y)0.13
Revenue GrowthN/A
EPS Growth-63.18%
CountryUS
Employees5
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.07
Shares Outstanding44,538,105
10 Day Avg. Volume1,247,655
30 Day Avg. Volume874,956
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)-6.72
Price to Sales (P/S)0.00
P/FCF Ratio>-0.01
Enterprise Value/Market Cap6.55
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-1.39K
Enterprise Value/Ebitda-14.46
Forecast
1Y Price Target
$8.67Price Target Upside501.85% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.7
Revenue Forecast (FY)$2.67M
OS Therapies Incorporated Business Overview & Revenue Model
Company Description
OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an...
How the Company Makes Money
null...
OS Therapies Incorporated Financial Statement Overview
Summary
Income Statement
6
Very Negative
Balance Sheet
18
Very Negative
Cash Flow
12
Very Negative
| Breakdown | Mar 2026 | Mar 2025 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -363.08K | -2.78K | -4.22K | -805.00 | -1.16M |
| EBITDA | -28.39M | -6.83M | -4.34M | -4.45M | -4.84M |
| Net Income | -28.75M | -8.88M | -7.79M | -6.25M | -7.42M |
Balance Sheet | |||||
| Total Assets | 6.84M | 5.54M | 798.08K | 509.11K | 325.89K |
| Cash, Cash Equivalents and Short-Term Investments | 269.83K | 5.53M | 38.98K | 171.48K | 80.79K |
| Total Debt | 0.00 | 0.00 | 14.61M | 10.35M | 7.07M |
| Total Liabilities | 12.94M | 4.73M | 24.81M | 18.07M | 11.78M |
| Stockholders Equity | -6.10M | 811.49K | -24.02M | -17.56M | -11.45M |
Cash Flow | |||||
| Free Cash Flow | -14.24B | -7.28M | -3.01M | -3.79M | -4.41M |
| Operating Cash Flow | -14.24B | -7.28M | -3.01M | -3.79M | -4.40M |
| Investing Cash Flow | -466.42M | 0.00 | 1.15K | 230.88K | 200.47K |
| Financing Cash Flow | 9.44B | 12.78M | 2.87M | 3.65M | 3.05M |
OS Therapies Incorporated Risk Analysis
OS Therapies Incorporated disclosed 63 risk factors in its most recent earnings report. OS Therapies Incorporated reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
OS Therapies Incorporated Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
49 Neutral | $77.63M | -3.07 | -201.43% | ― | ― | 33.86% | |
47 Neutral | $76.61M | -1.56 | 3214.88% | ― | ― | -63.18% | |
46 Neutral | $82.96M | -1.08 | -318.08% | ― | ― | 20.55% | |
42 Neutral | $30.43M | -1.25 | -218.67% | ― | ― | 48.96% |
* General Sector Average
OSTX
OS Therapies Incorporated
1.68
-0.02
-1.18%
ATNM
Actinium Pharmaceuticals
0.93
-0.59
-38.82%
ANVS
Annovis Bio
1.86
-0.85
-31.37%
GANX
Gain Therapeutics
1.80
0.07
4.05%
OS Therapies Incorporated Corporate Events
Business Operations and StrategyExecutive/Board ChangesPrivate Placements and Financing
OS Therapies Secures Convertible Note Financing for Expansion
Positive
Jul 2, 2026
On June 30, 2026, OS Therapies and its subsidiaries entered a private placement with Leonite Fund I for a senior secured convertible note of up to $10 million, with an initial $1.6 million tranche funded on July 2 and follow-on tranches at the inv...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
OS Therapies Gains EMA Rolling Review for OST-HER2
Positive
Apr 30, 2026
On April 30, 2026, OS Therapies announced that the European Medicines Agency has begun a rolling review of its conditional marketing authorization application for OST-HER2 in preventing or delaying recurrence of fully resected pulmonary metastatic...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.